AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
113 hedge funds and large institutions have $847M invested in AMAG Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 29 increasing their positions, 40 reducing their positions, and 16 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
63% more capital invested
Capital invested by funds: $520M → $847M (+$327M)
13% more funds holding
Funds holding: 100 → 113 (+13)
3% more call options, than puts
Call options by funds: $5.17M | Put options by funds: $5.03M
28% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$26.3M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$17.3M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$16M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
+$14.2M |
| 5 |
AP
Alydar Partners
Boston,
Massachusetts
|
+$6.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$20.7M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$17.6M |
| 3 |
BC
Broadfin Capital
New York
|
-$9.6M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$6.35M |
| 5 |
Morgan Stanley
New York
|
-$5.49M |
AMAG Hedge Fund Activity: Q3 2014 in Review
113 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q3 2014, worth a combined $847M — up 63% from $520M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AMAG positions and 16 closed out — a net gain of 13 holders — while 29 added to existing stakes and 40 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $26.3M. The largest seller was Deerfield Management, exiting entirely with an estimated $20.7M sold.
- 113 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q3 2014, up from 100 in Q2 2014.
- Funds reported $847M of AMAG Pharmaceuticals stock for Q3 2014, up 63% quarter-over-quarter.
- 29 funds opened new AMAG Pharmaceuticals positions in Q3 2014 and 16 closed out, a net change of +13 holders.
- The largest AMAG Pharmaceuticals buyer in Q3 2014 was Westfield Capital Management, an estimated $26.3M added.
- The largest AMAG Pharmaceuticals seller in Q3 2014 was Deerfield Management, an estimated $20.7M sold.
Based on aggregated 13F filings for Q3 2014.